Literature DB >> 30635258

Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases.

Michael Schwarz1, Florian Kocher2, Dora Niedersuess-Beke1, Jakob Rudzki2, Maximilian Hochmair3, Gerlig Widmann4, Wolfgang Hilbe1, Andreas Pircher5.   

Abstract

Entities:  

Keywords:  Case report; Checkpoint inhibitors; Glucocorticoids; Immune checkpoint blockade; Pneumonitis

Mesh：

Substances：

Year:  2018        PMID： 30635258     DOI： 10.1016/j.cllc.2018.12.006

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  9 in total

1.  Pneumocystis Infection in Two Patients Treated with Both Immune Checkpoint Inhibitor and Corticoids.

Authors:  Maroun Sadek; Angela Loizidou; Annie Drowart; Sigi Van den Wijngaert; Maria Gomez-Galdon; Sandrine Aspeslagh
Journal:  J Immunother Precis Oncol       Date:  2020-02-10

2.  Considerations for cancer immunotherapy during the COVID-19 pandemic.

Authors:  Yada Kanjanapan; Desmond Yip
Journal:  Med J Aust       Date:  2020-10-08       Impact factor: 7.738

Review 3.  [Pneumocystis jirovecii Pneumonia in Patients with Lung Cancer: A Review].

Authors:  Ting Li; Jianying Zhou; Qing Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-03-28

4.  Pneumocystis pneumonia in patient with lung adenocarcinoma: early side effects from pembrolizumab.

Authors:  Zahi Hiba; Hosni Abdelmoughit; Iraqi Houssaini Zaynab; Jerguigue Hounaida; Latib Rachida; Omor Youssef
Journal:  Radiol Case Rep       Date:  2022-08-17

5.  Not COVID-19, Don't Overlook Pneumocystis in Patients on Gefitinib!

Authors:  Jérémy Barben; Valérie Quipourt; Jérémie Vovelle; Alain Putot; Patrick Manckoundia
Journal:  Curr Oncol       Date:  2021-02-21       Impact factor: 3.677

6.  Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity.

Authors:  Karla A Lee; Heather Shaw; Véronique Bataille; Paul Nathan
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

Review 7.  Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.

Authors:  Ioannis Kyriakidis; Eleni Vasileiou; Claudia Rossig; Emmanuel Roilides; Andreas H Groll; Athanasios Tragiannidis
Journal:  J Fungi (Basel)       Date:  2021-03-05

Review 8.  Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy.

Authors:  Tommaso Morelli; Kohei Fujita; Gil Redelman-Sidi; Paul T Elkington
Journal:  Thorax       Date:  2021-10-04       Impact factor: 9.139

9.  Incidence of Infections and Predictors of Mortality During Checkpoint Inhibitor Immunotherapy in Patients With Advanced Lung Cancer: A Retrospective Cohort Study.

Authors:  Davide Fiore Bavaro; Pamela Pizzutilo; Annamaria Catino; Fabio Signorile; Francesco Pesola; Francesco Di Gennaro; Sandro Cassiano; Ilaria Marech; Vito Lamorgese; Gioacchino Angarano; Laura Monno; Annalisa Saracino; Domenico Galetta
Journal:  Open Forum Infect Dis       Date:  2021-04-13       Impact factor: 3.835
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.